Xconomy.com -- ZymoGenetics, the Seattle-based biotech company, said today that it generated $6 million in second-quarter sales of recombinant thrombin (Recothrom). That performance is an improvement on the $4.5 million the company reported in the first quarter, and puts ZymoGenetics (NASDAQ: ZGEN) on pace to reach its 2009 sales forecast of $25 million to $35 million.
